HOPE-3 Cardiac Endpoint Misses Significance, Tempering Deramiocel Data
CAPR has more than doubled off its 52-week low of $2.96.
Summary
The HOPE-3 key secondary endpoint — change in LVEF across all patients — came in at p=0.09, missing statistical significance. That undercuts the cardiac side of the deramiocel story, which had been a supporting pillar after the trial hit its primary upper limb function endpoint (PUL 2.0, p=0.029) in August. The trial randomized 106 patients over 12 months, so the evidence base is small and the cardiac readout is now the weak link. The BLA remains under FDA review with a PDUFA target action date of November 22, 2026 — that decision is the binary event that matters, and it is now roughly two weeks out. This follows the August 24 three-month PDUFA extension and the 24-month open-label data presented in late September and early October.
At the time of this announcement, CAPR was trading at $9.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $523.3M. The 52-week trading range was $2.96 to $40.37. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.